CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 32 enrolled
Drug / intervention
florbetapir F 18drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01565291
NCT01565291Early Ph 1Completed
CompareCT.gov

A Preliminary Evaluation of the Amyloid Binding Properties, Pharmacokinetics and Safety of 18F-AV-45 in Healthy Elderly Volunteers and Patients With Alzheimer's Disease

Avid Radiopharmaceuticals·interventional·Posted Mar 28, 2012·Updated May 18, 2012

In Brief

A Early Phase 1 clinical trial evaluating florbetapir F 18 for Alzheimer Disease. Completed, enrolled 32 participants across 3 sites.

Detailed Summary

A preliminary study to test how florbetapir F 18 (18F-AV-45) acts in the brains and bodies of healthy elderly people and patients with Alzheimer's Disease (AD) by using a positron emission tomography (PET) scanner.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited States
Collaborators--

Timeline

Early Ph 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 28, 2012
Enrollment StartJun 1, 2007
Primary CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 14.3 years ago

Interventions

florbetapir F 18drug

IV injection, 370MBq (10mCi), single dose